Beam Therapeutics Inc. Direct Financing Lease, Residual Value of Leased Asset
Beam Therapeutics Inc. (BEAM) had Direct Financing Lease, Residual Value of Leased Asset of $675.00 thousand as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Leases
us-gaap:DirectFinancingLeaseResidualValueOfLeasedAsset · last filed 2023-02-28
- 2022-12-31: Direct Financing Lease, Residual Value of Leased Asset $675.00K.
| Period end | Direct Financing Lease, Residual Value of Leased Asset |
|---|---|
| 2022-12-31 | $675.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |